Discontinued — last reported Q4 '25
McKesson Provision for Credit Losses decreased by 519.4% to -$151.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 704.0%, from $25.00M to -$151.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests management expects higher default rates or a deteriorating credit environment, while a decrease suggests improved borrower quality.
This represents the non-cash expense set aside by a financial institution to cover potential losses from loans or credit...
Common in banking and credit card issuers; peers adjust this based on macroeconomic forecasts and portfolio seasoning.
provision_for_credit_losses_cf| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q2 '24 | Q3 '24 | Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.25M | $7.25M | $7.25M | $7.25M | $11.25M | $11.25M | $11.25M | $11.25M | $6.00M | $237.00M | $15.00M | -$184.00M | $25.00M | $196.00M | $36.00M | -$151.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +55.2% | +0.0% | +0.0% | +0.0% | -46.7% | >999% | -93.7% | <-999% | +113.6% | +684.0% | -81.6% | -519.4% |
| YoY Change | — | — | — | — | +55.2% | +55.2% | +55.2% | +55.2% | -46.7% | >999% | +150.0% | -177.6% | — | >999% | +119.6% | -704.0% |
| Segment | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | $181.25M | — | $181.25M | -$203.00M | — | -$52.50M | -$52.50M | -$52.50M |
| U.S. Pharmaceutical | $210.00M | $515.00M | — | — | $189.00M | — | — | — |
| Total | $237.00M | — | — | -$184.00M | $196.00M | $36.00M | -$151.00M | — |
U.S. Pharmaceutical was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.